Zoetis (ZTS)
(Delayed Data from NYSE)
$190.03 USD
-0.96 (-0.50%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $189.97 -0.06 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$190.03 USD
-0.96 (-0.50%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $189.97 -0.06 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
Zacks News
PCRX vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PCRX vs. ZTS: Which Stock Is the Better Value Option?
Top Research Reports for Amgen, BHP, Altria & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), BHP Group (BHP) and Altria Group (MO).
Zoetis' (ZTS) Q1 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Zoetis (ZTS) beats on earnings in the first quarter of 2020 while sales meet estimates. Domestic revenues bumped up owing to growth in new parasiticide products and a robust dermatology portfolio.
Zoetis (ZTS) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 7.95% and 1.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q1 Earnings Due on May 6: ZTS, ALXN & More
by Kinjel Shah
Let us take a look at five drug/biotech companies due to release their first-quarter financial results on May 6.
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) will provide pipeline updates along with financial numbers for the first quarter in its impending earnings release.
Zoetis (ZTS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Zoetis (ZTS) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
GRFS vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
GRFS vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Tesla, Zoetis, Target, Boston Scientific and Moody's
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tesla, Zoetis, Target, Boston Scientific and Moody's
Top Research Reports for Tesla, Zoetis, Target
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Tesla (TSLA), Zoetis (ZTS) and Target (TGT).
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEF
Zoetis (ZTS) Down 13.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PCRX or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PCRX vs. ZTS: Which Stock Is the Better Value Option?
PCRX vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
PCRX vs. ZTS: Which Stock Is the Better Value Option?
Stock Market News for Feb 14, 2020
by Zacks Equity Research
U.S. stocks slid Thursday following a massive jump in coronavirus cases.
Zoetis' (ZTS) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Zoetis (ZTS) beats on both earnings and sales in the fourth quarter of 2019.
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis Inc. (ZTS) will provide financial numbers for fourth-quarter 2019 and pipeline updates on Feb 13.
Zoetis (ZTS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMRX vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMRX vs. ZTS: Which Stock Is the Better Value Option?
Can Zoetis (ZTS) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEF
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Texas Instruments, Charter, Lowe's, Caterpillar and Zoetis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Texas Instruments, Charter, Lowe's, Caterpillar and Zoetis